SA03240344B1 - طريقة لانتاج مركب بنزايميدازول - Google Patents
طريقة لانتاج مركب بنزايميدازول Download PDFInfo
- Publication number
- SA03240344B1 SA03240344B1 SA03240344A SA03240344A SA03240344B1 SA 03240344 B1 SA03240344 B1 SA 03240344B1 SA 03240344 A SA03240344 A SA 03240344A SA 03240344 A SA03240344 A SA 03240344A SA 03240344 B1 SA03240344 B1 SA 03240344B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- water
- reaction
- organic solvent
- methoxy
- chloride
- Prior art date
Links
- -1 benzimidazole compound Chemical class 0.000 title claims description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 48
- PSEPRWKZZJWRCB-UHFFFAOYSA-N (4-methoxy-3,5-dimethylpyridin-2-yl)methanol Chemical compound COC1=C(C)C=NC(CO)=C1C PSEPRWKZZJWRCB-UHFFFAOYSA-N 0.000 claims abstract description 35
- XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 claims abstract description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 26
- 239000003960 organic solvent Substances 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 35
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 28
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000640 hydroxylating effect Effects 0.000 claims description 8
- 239000000543 intermediate Substances 0.000 claims description 6
- 238000005906 dihydroxylation reaction Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract description 12
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 abstract description 12
- 229960004770 esomeprazole Drugs 0.000 abstract description 12
- 229960000381 omeprazole Drugs 0.000 abstract description 12
- 238000002955 isolation Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- KOFBRZWVWJCLGM-UHFFFAOYSA-N 5-methoxy-1,3-dihydrobenzimidazole-2-thione Chemical compound COC1=CC=C2NC(S)=NC2=C1 KOFBRZWVWJCLGM-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203092A SE0203092D0 (en) | 2002-10-18 | 2002-10-18 | Method for the synthesis of a benzimidazole compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA03240344B1 true SA03240344B1 (ar) | 2008-09-14 |
Family
ID=20289310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA03240344A SA03240344B1 (ar) | 2002-10-18 | 2003-10-14 | طريقة لانتاج مركب بنزايميدازول |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7227024B2 (https=) |
| EP (1) | EP1556370B1 (https=) |
| JP (1) | JP4551221B2 (https=) |
| KR (1) | KR101065885B1 (https=) |
| CN (2) | CN100374436C (https=) |
| AR (1) | AR041639A1 (https=) |
| AT (1) | ATE398118T1 (https=) |
| AU (1) | AU2003269773B2 (https=) |
| BR (1) | BR0315254A (https=) |
| CA (1) | CA2501542C (https=) |
| CY (1) | CY1108255T1 (https=) |
| DE (1) | DE60321588D1 (https=) |
| DK (1) | DK1556370T3 (https=) |
| ES (1) | ES2306883T3 (https=) |
| IL (1) | IL167795A (https=) |
| IS (1) | IS2590B (https=) |
| MX (1) | MXPA05003994A (https=) |
| MY (1) | MY133573A (https=) |
| NO (1) | NO330785B1 (https=) |
| NZ (1) | NZ539370A (https=) |
| PL (1) | PL376819A1 (https=) |
| PT (1) | PT1556370E (https=) |
| RU (1) | RU2324691C2 (https=) |
| SA (1) | SA03240344B1 (https=) |
| SE (1) | SE0203092D0 (https=) |
| SI (1) | SI1556370T1 (https=) |
| TW (1) | TWI310382B (https=) |
| UA (1) | UA79147C2 (https=) |
| UY (1) | UY28025A1 (https=) |
| WO (1) | WO2004035565A1 (https=) |
| ZA (1) | ZA200502577B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0203092D0 (en) | 2002-10-18 | 2002-10-18 | Astrazeneca Ab | Method for the synthesis of a benzimidazole compound |
| US8691995B2 (en) | 2004-12-16 | 2014-04-08 | Cipla Limited | Process |
| WO2010134099A1 (en) | 2009-05-21 | 2010-11-25 | Cadila Healthcare Limited | One pot process for preparing omeprazole and related compounds |
| CN102884178B (zh) | 2009-12-08 | 2014-12-03 | 科德克希思公司 | 拉唑化合物的合成 |
| HUE037616T2 (hu) | 2010-12-08 | 2018-09-28 | Codexis Inc | Biokatalizátorok és eljárások armodafinil szintéziséhez |
| CN103570681A (zh) * | 2012-07-24 | 2014-02-12 | 江苏柯菲平医药有限公司 | 一种埃索美拉唑关键中间体的制备方法 |
| CN103232389A (zh) * | 2013-05-08 | 2013-08-07 | 浙江新三和医药化工股份有限公司 | 2-氯甲基-4-甲氧基-3,5-二甲基吡啶盐酸盐的制备方法 |
| CN103524494A (zh) * | 2013-11-07 | 2014-01-22 | 安徽国星生物化学有限公司 | 含甲基吡啶基团的巯基咪唑类衍生物及合成方法 |
| CN108251466B (zh) * | 2016-12-28 | 2021-07-02 | 浙江京新药业股份有限公司 | 一种酶法合成埃索美拉唑的方法 |
| CN107400118B (zh) * | 2017-08-29 | 2020-07-28 | 信泰制药（苏州）有限公司 | 埃索美拉唑中间体的制备方法 |
| CN111943883A (zh) * | 2020-08-21 | 2020-11-17 | 抚州三和医药化工有限公司 | 一种奥美氯化物的生产工艺 |
| KR20220084718A (ko) | 2020-12-14 | 2022-06-21 | 메디케어제약 주식회사 | 기능성 소화 불량을 동반한 위식도 역류 질환을 치료하는 약제학적 복합제제 |
| KR20230090184A (ko) | 2021-12-14 | 2023-06-21 | 메디케어제약 주식회사 | 에스오메프라졸 및 레바미피드를 포함하는 약제학적 복합제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4619997A (en) * | 1984-09-06 | 1986-10-28 | The Upjohn Company | Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents |
| SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
| WO1993006097A1 (en) * | 1991-09-20 | 1993-04-01 | Merck & Co., Inc. | Novel process for the preparation of anti-ulcer agents |
| ES2142065T3 (es) * | 1995-07-03 | 2000-04-01 | Asahi Chemical Ind | Clorhidratos de 1-(5-isoquinoleinsulfonil)homopiperazina hidratado. |
| SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
| SE9704183D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New process |
| SI20019A (sl) * | 1998-07-13 | 2000-02-29 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola |
| SE0203092D0 (en) | 2002-10-18 | 2002-10-18 | Astrazeneca Ab | Method for the synthesis of a benzimidazole compound |
-
2002
- 2002-10-18 SE SE0203092A patent/SE0203092D0/xx unknown
-
2003
- 2003-10-09 TW TW092128112A patent/TWI310382B/zh not_active IP Right Cessation
- 2003-10-14 SA SA03240344A patent/SA03240344B1/ar unknown
- 2003-10-15 UA UAA200502927A patent/UA79147C2/uk unknown
- 2003-10-15 WO PCT/SE2003/001602 patent/WO2004035565A1/en not_active Ceased
- 2003-10-15 AU AU2003269773A patent/AU2003269773B2/en not_active Expired
- 2003-10-15 MX MXPA05003994A patent/MXPA05003994A/es active IP Right Grant
- 2003-10-15 BR BR0315254-5A patent/BR0315254A/pt not_active IP Right Cessation
- 2003-10-15 DE DE60321588T patent/DE60321588D1/de not_active Expired - Lifetime
- 2003-10-15 SI SI200331301T patent/SI1556370T1/sl unknown
- 2003-10-15 PL PL376819A patent/PL376819A1/pl unknown
- 2003-10-15 ES ES03751703T patent/ES2306883T3/es not_active Expired - Lifetime
- 2003-10-15 DK DK03751703T patent/DK1556370T3/da active
- 2003-10-15 AT AT03751703T patent/ATE398118T1/de active
- 2003-10-15 EP EP03751703A patent/EP1556370B1/en not_active Expired - Lifetime
- 2003-10-15 KR KR1020057006554A patent/KR101065885B1/ko not_active Expired - Fee Related
- 2003-10-15 PT PT03751703T patent/PT1556370E/pt unknown
- 2003-10-15 NZ NZ539370A patent/NZ539370A/en not_active IP Right Cessation
- 2003-10-15 CN CNB2003801014302A patent/CN100374436C/zh not_active Expired - Lifetime
- 2003-10-15 RU RU2005109270/04A patent/RU2324691C2/ru active
- 2003-10-15 CA CA2501542A patent/CA2501542C/en not_active Expired - Fee Related
- 2003-10-15 JP JP2004545137A patent/JP4551221B2/ja not_active Expired - Fee Related
- 2003-10-15 CN CN2008100040145A patent/CN101230057B/zh not_active Expired - Lifetime
- 2003-10-15 US US10/531,412 patent/US7227024B2/en not_active Expired - Lifetime
- 2003-10-16 MY MYPI20033949A patent/MY133573A/en unknown
- 2003-10-16 UY UY28025A patent/UY28025A1/es not_active Application Discontinuation
- 2003-10-16 AR ARP030103769A patent/AR041639A1/es not_active Application Discontinuation
-
2005
- 2005-03-30 ZA ZA200502577A patent/ZA200502577B/en unknown
- 2005-03-31 IL IL167795A patent/IL167795A/en not_active IP Right Cessation
- 2005-05-02 NO NO20052158A patent/NO330785B1/no not_active IP Right Cessation
- 2005-05-03 IS IS7834A patent/IS2590B/is unknown
-
2007
- 2007-05-16 US US11/749,282 patent/US7683178B2/en not_active Expired - Lifetime
-
2008
- 2008-08-12 CY CY20081100852T patent/CY1108255T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA03240344B1 (ar) | طريقة لانتاج مركب بنزايميدازول | |
| CA2404621A1 (fr) | Procede de preparation de la (2s,3r,4s)-4-hydroxyisoleucine et de ses analogues | |
| EP1841745B1 (en) | Process for the manufacture of a precursor of vitamin b1 | |
| EP0143973B1 (en) | Method of producing (s)-glyceraldehyde acetonide | |
| EP0024241B1 (fr) | Nouveaux composés sulfonés comportant un cycle lactonique, ainsi qu'un procédé de préparation de dérivés cyclopropaniques | |
| CA2698160C (en) | Stabilized doxercalciferol and process for manufacturing the same | |
| EP0769493B1 (fr) | Procédé de préparation de (méth)acrylates d'alkylimidazolidone | |
| EA015270B1 (ru) | Способ получения промежуточных соединений хлорамфеникола или его аналогов | |
| CN110204587B (zh) | 一种奥贝胆酸的合成方法 | |
| KR100518933B1 (ko) | 옥사졸린-아제티디논 유도체의 정제방법 | |
| KR20000030018A (ko) | 광학활성에리스로-3-아미노-2-히드록시부티르산에스테르류및해당부티르산류의제조방법 | |
| AT401177B (de) | Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsäure-derivaten | |
| FR2587030A1 (fr) | Bis(2-gluconamidoalkyl)disulfures | |
| JP4631262B2 (ja) | （シス）−４−ヒドロキシプロリン誘導体の製造方法 | |
| EP0821697A1 (fr) | Procede de preparation de streptogramines | |
| WO2007070238A3 (en) | Processes for the preparation of modafinil and analogs thereof | |
| FR2636624A1 (fr) | Procede d'inversion stereochimique d'une fonction hydroxy d'un ester par un processus reactionnel de mitsunobu modifie | |
| EP0539450B1 (fr) | Procede de preparation de sulfinyl pristinamycine ii b | |
| JP2017210468A (ja) | ヨードラクトン化合物の製造方法 | |
| EP0555483B1 (en) | Process for producing azacycloalkane derivative | |
| DE60026407D1 (de) | Verfahren zur Herstellung von Vitamin-D Analogen | |
| JP4870296B2 (ja) | ヒノキチオール配糖体の製造方法 | |
| KR920000694B1 (ko) | 디펩타이드유도체의 제조방법 | |
| JP2023155765A (ja) | アミド化合物の製造方法 | |
| Johannesen et al. | Radical addition of nitrones to acrylates mediated by SmI 2: asymmetric synthesis of γ-amino acids employing carbohydrate-based chiral auxiliaries |